Cargando…

P083 Susceptibility pattern of fungal isolated from patients with otomycosis

POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: Antifungal resistance is posing several new concerns to clinicians. Increased rates of azole and echinocandin resistance in various non-albicans Candida species and azole resistance in A. fumigatus may arise due to clinical or e...

Descripción completa

Detalles Bibliográficos
Autores principales: Shokohi, Tahereh, Roohi, Behrad, Nemati, Shadman, Alipour, Abbas, Faeli, Leila, Mayahi, Sabah, Haghani, Iman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509965/
http://dx.doi.org/10.1093/mmy/myac072.P083
_version_ 1784797345764868096
author Shokohi, Tahereh
Roohi, Behrad
Nemati, Shadman
Alipour, Abbas
Faeli, Leila
Mayahi, Sabah
Haghani, Iman
author_facet Shokohi, Tahereh
Roohi, Behrad
Nemati, Shadman
Alipour, Abbas
Faeli, Leila
Mayahi, Sabah
Haghani, Iman
author_sort Shokohi, Tahereh
collection PubMed
description POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: Antifungal resistance is posing several new concerns to clinicians. Increased rates of azole and echinocandin resistance in various non-albicans Candida species and azole resistance in A. fumigatus may arise due to clinical or environmental exposure to these drugs. The study evaluated the antifungal susceptibility for clinical fungal isolates causing otomycosis. METHODS: A total of 89 Aspergillus isolates containing A. niger (58 isolates), A. flavus (19 isolates), A. fumigatus (12 isolates), and 25 Candida isolates containing C. parapsilosis (14 isolates), C. orthopsilosis (6 isolates), and C. albicans (5 isolates) collected from individuals with confirmed otomycosis during October 2020-November 2021 were tested for antifungal susceptibility testing (AFST). AFST of ketoconazole, voriconazole, tioconazole, amphotericin B, miconazole, fluconazole, nystatin, and itraconazole was conducted using the broth microdilution method based on CLSI (M38-A2, M27-A3) protocols. Conidia of molds and colonies of yeasts were harvested from fungal cultures on SDA incubated at 35°C; the turbidity of the suspension was then adjusted to OD630 nm = 80%-82%T for molds and 75%-77%T for yeasts. RESULTS: Mainly, all antifungals examined were effective against most Aspergillus isolates, aside from tioconazole (GM = 5.54767 μg/ml) and nystatin (GM = 2.10151 μg/ml). Terbinafine (GM = 1.69824 μg/ml) had minimal in vitro effects (Table 1). Nystatin (GM = 2.94853 μg/ml) and itraconazole (GM = 1.08673 μg/ml) showed higher GM MICs against all Candida species isolates. Conversely, amphotericin B (GM = 0.07129 μg/ml) in Aspergillus, ketoconazole (GM = 0.02570), and voriconazole (GM = 0.03686 μg/ml) in Candida showed the highest antifungal activity (Table 2). Regarding the CLSI-M59 document for ECV, one A. niger (MIC 8 μg/ml), A. flavus (MIC 2 μg/ml), and A. fumigatus (MIC 2 μg/ml) isolates were non-wild type against itraconazole. A total of 3 A. niger non-wild type isolates with MIC 4 μg/ml against voriconazole were inspected (Table 1). Three C. albicans isolates with high itraconazole MICs (two 8 μg/ml and one 16 μg/ml) were observed (Table 2). Even though the MIC50 of Aspergillus niger for tolnaftate was 0.37 μg/ml, 9 isolates with high MICs (16 μg/ml) were found. CONCLUSION: The foremost commonest yeast isolates in this study, C. parapsilosis, exhibit significant sensitivity to various antifungals, including ketoconazole, voriconazole, tioconazole, amphotericin B, miconazole, fluconazole, and itraconazole. However, contrary to other studies, nystatin had high MICs and is not recommended as an effective drug. Since the pattern of antifungal susceptibility is varied among the cryptic species of Aspergillus sections, we recommend that physicians request a drug susceptibility testing before antibiotic therapy to prevent the development of resistance.
format Online
Article
Text
id pubmed-9509965
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95099652022-09-26 P083 Susceptibility pattern of fungal isolated from patients with otomycosis Shokohi, Tahereh Roohi, Behrad Nemati, Shadman Alipour, Abbas Faeli, Leila Mayahi, Sabah Haghani, Iman Med Mycol Oral Presentations POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: Antifungal resistance is posing several new concerns to clinicians. Increased rates of azole and echinocandin resistance in various non-albicans Candida species and azole resistance in A. fumigatus may arise due to clinical or environmental exposure to these drugs. The study evaluated the antifungal susceptibility for clinical fungal isolates causing otomycosis. METHODS: A total of 89 Aspergillus isolates containing A. niger (58 isolates), A. flavus (19 isolates), A. fumigatus (12 isolates), and 25 Candida isolates containing C. parapsilosis (14 isolates), C. orthopsilosis (6 isolates), and C. albicans (5 isolates) collected from individuals with confirmed otomycosis during October 2020-November 2021 were tested for antifungal susceptibility testing (AFST). AFST of ketoconazole, voriconazole, tioconazole, amphotericin B, miconazole, fluconazole, nystatin, and itraconazole was conducted using the broth microdilution method based on CLSI (M38-A2, M27-A3) protocols. Conidia of molds and colonies of yeasts were harvested from fungal cultures on SDA incubated at 35°C; the turbidity of the suspension was then adjusted to OD630 nm = 80%-82%T for molds and 75%-77%T for yeasts. RESULTS: Mainly, all antifungals examined were effective against most Aspergillus isolates, aside from tioconazole (GM = 5.54767 μg/ml) and nystatin (GM = 2.10151 μg/ml). Terbinafine (GM = 1.69824 μg/ml) had minimal in vitro effects (Table 1). Nystatin (GM = 2.94853 μg/ml) and itraconazole (GM = 1.08673 μg/ml) showed higher GM MICs against all Candida species isolates. Conversely, amphotericin B (GM = 0.07129 μg/ml) in Aspergillus, ketoconazole (GM = 0.02570), and voriconazole (GM = 0.03686 μg/ml) in Candida showed the highest antifungal activity (Table 2). Regarding the CLSI-M59 document for ECV, one A. niger (MIC 8 μg/ml), A. flavus (MIC 2 μg/ml), and A. fumigatus (MIC 2 μg/ml) isolates were non-wild type against itraconazole. A total of 3 A. niger non-wild type isolates with MIC 4 μg/ml against voriconazole were inspected (Table 1). Three C. albicans isolates with high itraconazole MICs (two 8 μg/ml and one 16 μg/ml) were observed (Table 2). Even though the MIC50 of Aspergillus niger for tolnaftate was 0.37 μg/ml, 9 isolates with high MICs (16 μg/ml) were found. CONCLUSION: The foremost commonest yeast isolates in this study, C. parapsilosis, exhibit significant sensitivity to various antifungals, including ketoconazole, voriconazole, tioconazole, amphotericin B, miconazole, fluconazole, and itraconazole. However, contrary to other studies, nystatin had high MICs and is not recommended as an effective drug. Since the pattern of antifungal susceptibility is varied among the cryptic species of Aspergillus sections, we recommend that physicians request a drug susceptibility testing before antibiotic therapy to prevent the development of resistance. Oxford University Press 2022-09-20 /pmc/articles/PMC9509965/ http://dx.doi.org/10.1093/mmy/myac072.P083 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Shokohi, Tahereh
Roohi, Behrad
Nemati, Shadman
Alipour, Abbas
Faeli, Leila
Mayahi, Sabah
Haghani, Iman
P083 Susceptibility pattern of fungal isolated from patients with otomycosis
title P083 Susceptibility pattern of fungal isolated from patients with otomycosis
title_full P083 Susceptibility pattern of fungal isolated from patients with otomycosis
title_fullStr P083 Susceptibility pattern of fungal isolated from patients with otomycosis
title_full_unstemmed P083 Susceptibility pattern of fungal isolated from patients with otomycosis
title_short P083 Susceptibility pattern of fungal isolated from patients with otomycosis
title_sort p083 susceptibility pattern of fungal isolated from patients with otomycosis
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509965/
http://dx.doi.org/10.1093/mmy/myac072.P083
work_keys_str_mv AT shokohitahereh p083susceptibilitypatternoffungalisolatedfrompatientswithotomycosis
AT roohibehrad p083susceptibilitypatternoffungalisolatedfrompatientswithotomycosis
AT nematishadman p083susceptibilitypatternoffungalisolatedfrompatientswithotomycosis
AT alipourabbas p083susceptibilitypatternoffungalisolatedfrompatientswithotomycosis
AT faelileila p083susceptibilitypatternoffungalisolatedfrompatientswithotomycosis
AT mayahisabah p083susceptibilitypatternoffungalisolatedfrompatientswithotomycosis
AT haghaniiman p083susceptibilitypatternoffungalisolatedfrompatientswithotomycosis